Drugs / Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05043610 | Sep 2021 → Nov 2024 | ST-elevation myocardial infarction, heart failure | Shiraz University of Medical Sciences | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05043610 ↗ |
| Known as | WJ-MSCs | “cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route.” NCT05043610 ↗ |
| Modality | Cell therapy | “intracoronary infusion of umbilical cord-derived Wharton's jelly MSCs (WJ-MSCs)” NCT05043610 ↗ |
| Route | Other | “10\^7 WJ-MSCs will be delivered through the intracoronary route.” NCT05043610 ↗ |